Biomarin Pharmaceutical (BMRN) Convertible Debt (2009 - 2025)
Biomarin Pharmaceutical's (BMRN) quarterly Convertible Debt came in at $597.2 million in Q4 2025, little changed YoY from $595.1 million in Q4 2024, and little changed on a QoQ basis from $596.7 million in Q3 2025.
Biomarin Pharmaceutical (BMRN) Convertible Debt (2009 - 2025) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 17 years of Convertible Debt data on file, last reported at $597.2 million in Q4 2025.
- Quarterly Convertible Debt changed 0.34% year-over-year to $597.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $597.2 million (changed 0.34% YoY) and the FY2025 annual result came in at $597.2 million, changed 0.34% from the prior year.
- Convertible Debt held at $597.2 million in Q4 2025, from $596.7 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $1.1 billion in Q1 2024 to a low of $592.6 million in Q3 2023.
- A 5-year average of $887.1 million and a median of $1.1 billion in 2021 frame the typical range for Convertible Debt.
- Annual changes were most pronounced in 2021 — Convertible Debt surged 121.1% — and 2025, when it slumped 45.25%.
- Tracing BMRN's Convertible Debt over 5 years: stood at $1.1 billion in 2021, then increased by 0.37% to $1.1 billion in 2022, then gained by 0.36% to $1.1 billion in 2023, then tumbled by 45.25% to $595.1 million in 2024, then gained by 0.34% to $597.2 million in 2025.
- The last three Convertible Debt figures came in at $597.2 million (Q4 2025), $596.7 million (Q3 2025), and $596.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 597.18 Mn |
| Sep 30, 2025 | 596.66 Mn |
| Jun 30, 2025 | 596.16 Mn |
| Mar 31, 2025 | 595.65 Mn |
| Dec 31, 2024 | 595.14 Mn |
| Sep 30, 2024 | 594.63 Mn |
| Jun 30, 2024 | 594.12 Mn |
| Mar 31, 2024 | 1.09 Bn |
| Dec 31, 2023 | 1.09 Bn |
| Sep 30, 2023 | 592.59 Mn |
| Jun 30, 2023 | 1.08 Bn |
| Mar 31, 2023 | 1.08 Bn |
| Dec 31, 2022 | 1.08 Bn |
| Sep 30, 2022 | 1.08 Bn |
| Jun 30, 2022 | 1.08 Bn |
| Mar 31, 2022 | 1.08 Bn |
| Dec 31, 2021 | 1.08 Bn |
| Sep 30, 2021 | 1.08 Bn |
| Jun 30, 2021 | 1.08 Bn |
| Mar 31, 2021 | 1.08 Bn |